and , /PRNewswire-USNewswire/ -- The Florida Institute for the Commercialization of Public Research (the Florida Institute) announced today that it has finalized a funding agreement SegAna, LLC, an -based company with technology developed at . The Florida Institute supports new company creation based on publicly-funded research, and bridges early funding gaps for companies spinning out of Florida-based universities and research institutions.
SegAna is a medical technology company that will produce deformable four-dimensional lung phantom simulators for enhancing lung cancer radiation treatment. SegAna's lung phantoms are 3-D printed with patient specific details, including elastic and radiographic properties. The lung phantom, when coupled with SegAna's simulator, trains the physician to develop precise treatment parameters which are translated directly to the patient's radiation treatment.
"Lung cancer is the most common cancer worldwide and accounts for more deaths than any other cancer in the U.S.," said , SegAna, LLC, Chief Executive Officer. "Our patent pending state of art technology will enhance the treatment of lung cancer by training the physician to accurately treat the tumor during normal breathing of the lung, which reduces radiation damage to lung tissue surrounding the cancer and ultimately improving patient outcomes."
"There are over 220,000 new lung cancer cases reported annually in , and an estimated 80% of the cases are treated with radiation therapy," said , MD, Florida Institute Chief Executive Officer. "The Institute looks forward to supporting SegAna as the company works to improve lung cancer treatment and associated outcomes for patients fighting this disease."
About the Florida Institute